Bristol-Myers Squibb (NYSE:BMY) traded today at a new 52-week high of $42.87. So far today approximately 7.2 million shares have been exchanged, as compared to an average 30-day volume of 10.1 million shares.
Bristol-Myers Squibb (NYSE:BMY) defies analysts with a current price ($42.39) 13.7% above its average consensus price target of $36.57. The stock should find initial support at its 50-day moving average (MA) of $38.96 and further support at its 200-day MA of $34.92.
In the past 52 weeks, shares of Bristol-Myers Squibb have traded between a low of $30.64 and a high of $42.87 and are now at $42.39, which is 38% above that low price. The 200-day and 50-day moving averages have moved 0.24% higher and 0.73% higher over the past week, respectively.
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.